AI medtech company Weisen announced on the 12th that it signed a strategic business agreement with UAE medical device specialist Dhafir Medical to enter the Middle Eastern market at WHX 2026 (formerly Arab Health), one of the world's top three medical exhibitions held in Dubai, United Arab Emirates (UAE).
Under this agreement, the two companies plan to collaborate on the UAE business expansion of the AI endoscope 'Waymed Endo', as well as jointly promote medical AI education and clinical application support for medical professionals to expand the Middle Eastern market.
Waysen has already implemented and is operating WayMed Endo at a medical institution in Abu Dhabi, securing a local reference hospital. Interviews with medical staff at the hospital reportedly yielded positive reviews for its usability in real-world clinical settings, its effectiveness in assisting diagnosis, and its ability to improve workflow. The company described this as a case study demonstrating its potential for expansion into the UAE market.
This agreement was achieved with the support of the Korea Health Industry Development Institute (KHIDI) UAE branch. The KHIDI served as a bridge between the two companies' technological capabilities and market potential. Lee Young-ho, KHIDI UAE branch manager, stated that the agency has been supporting the expansion of Korean AI medical technology into the Middle Eastern market.
Dafir Medical is a medical device company headquartered in Abu Dhabi, with a distribution network spanning the UAE. Its client base includes major public healthcare institutions, including SEHA, DHA, and EHS, as well as medical institutions under the UAE Ministry of Health, private hospitals, and specialty clinics.
Weisen plans to leverage Dafir Medical's local network and distribution capabilities to expand the introduction of WayMed Endo, focusing on hospitals and screening centers in the UAE. Building on this momentum, the company plans to gradually expand the scope of AI endoscopy across the Middle East.
Dr. Samar, CEO of Dafir Medical, evaluated WayMed Endo as a product with high diagnostic accuracy and efficiency, and said that it has the potential to expand into the Middle Eastern market based on its universal usability and clinical data that can be used in public and private medical institutions.
Waysen CEO Kim Kyung-nam stated that WayMed Endo has generated overseas sales in Southeast Asia and that this agreement will serve as a catalyst for achieving success in the Middle East. He added that, starting with the UAE, the company will strengthen collaboration with local partners to expand AI technology across the Middle Eastern medical landscape.
- See more related articles
You must be logged in to post a comment.